Investigational drug · Phase 3
HS-10506
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Insomnia Disorder.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "HS-10506"
First trial start
2026
May 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HS-10506", any sponsor or status.
Conditions studied
As listed on its trial records.
- Insomnia Disorder
Approved drugs for the same conditions: Insomnia · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "HS-10506" as an intervention, largest first.
- A Study of HS-10506 in Chinese Patients With Insomnia DisorderPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07587385 · 732 participants (planned) · Start May 29, 2026 · Primary completion Jun 28, 2028
Drug: HS-10506; Placebo · For: Insomnia Disorder
- A Study to Evaluate the Safety of HS-10506 in Chinese Patients With Insomnia DisorderPivotal-lookingNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07677384 · 600 participants (planned) · Start Jun 12, 2026 · Primary completion Jun 30, 2029
Drug: HS-10506 · For: Insomnia Disorder
- Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia DisorderPivotal-lookingStatus unknown
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT06279286 · 312 participants (planned) · Start May 2024 · Primary completion Jan 2025
Drug: HS-10506; Placebo · For: Insomnia Disorder
Sites: Beijing, China
- Phase 1a Study in Healthy ParticipantsStatus unknown
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT05953506 · 52 participants (planned) · Start Jul 17, 2023 · Primary completion Dec 24, 2023
Drug: HS-10506; HS-10506 Placebo · For: Healthy
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07844967 · 32 participants (planned) · Start Jun 1, 2026 · Primary completion Jun 1, 2028
Drug: HS-10506 · For: Hepatic Impairment (Moderate or Mild) & Normal Hepatic Function
Sites: Hefei, China
- A Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10506 in Healthy Chinese Adult ParticipantsNot yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
NCT07535970 · 20 participants (planned) · Start Apr 30, 2026 · Primary completion Jul 30, 2026
Drug: HS-10506, Itraconazole · For: Healthy Participants
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Insomnia Disorder
- YZJ-1139Phase 31 trial
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Insomnia Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.